Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE          2018-04-18
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE          2017-05-26
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

CMA POLICY

The Canadian Medical Association (CMA), recognizing the unique requirements of those individuals suffering from terminal illness or chronic disease for which conventional therapies have not been effective and/or may cause unacceptable side effects,

Furthemore, there is a growing number of patients who are involved in the use of cannabis for medical purposes, and the need for a body of professionals to be trained in the management of these patients has increased.

The CMA has a long-standing tradition of supporting research, and it is important to ensure that research is conducted in a way that is consistent with the principles of good scientific practice.

This includes ensuring that research is conducted in a way that respects the rights of participants, and that the results of research are disseminated in a way that is consistent with the principles of good scientific practice.

The CMA supports the following recommendations:

1. Support the development of a research agenda in the area of medical cannabis that includes the evaluation of the efficacy, safety, and cost-effectiveness of cannabis for medical purposes.

2. Support the development of guidelines for the use of cannabis in the management of chronic pain and other chronic conditions.

3. Support the development of guidelines for the use of cannabis in the management of chronic pain and other chronic conditions.

4. Support the development of guidelines for the use of cannabis in the management of chronic pain and other chronic conditions.

5. Support the development of guidelines for the use of cannabis in the management of chronic pain and other chronic conditions.

The CMA believes that the use of cannabis for medical purposes should be regulated in a manner that is consistent with the principles of good scientific practice, and that research in this area should be conducted in a way that respects the rights of participants and the principles of good scientific practice.

CMA Policybase - Canadian Medical Association
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799

POLICY TYPE: Response to consultation
DATE: 2017-12-07
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE
Response to consultation

DATE
2018-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-09-03</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
The Health risks and harms associated with the use of marijuana
https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation
DATE  2016-08-29
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Proposed approach to the regulation of cannabis

https://policybase.cma.ca/link/policy13838

POLICY TYPE: Response to consultation
DATE: 2018-01-19
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents